65,437 trials
Neurofibromatosis Type 1 and Growing or Symptomatic, Inoperable PN
Primary: Percent of Participants With a 20% or More Change in Target Tumor Volume — 0; 8; 11; 0 Participants
HIV
Primary: Platelet Reactivity Measured by Expression of P-selectin (CD62p) and Fibrinogen Binding — 0.9; 0.96; 1; 0.99 Ratio
Advanced or Recurrent Solid Tumors · Breast Neoplasms · Ovarian Cancer, Epithelial
Primary: Number of Participants With Objective Response — 8; 12; 2; 0 participants
Ann Arbor Stage III Grade 1 Follicular Lymphoma · Ann Arbor Stage III Grade 2 Follicular Lymphoma · Ann Arbor Stage III Grade 3 Follicular Lymphoma
Primary: Complete Response Rate — .621; .597 proportion of patients
Fibromyalgia
Primary: Pain at Rest Difference Score Pre-intervention and Post Intervention — 0.38; -0.74; -0.47 units on a scale
Major Depressive Disorder
Primary: Percentage of Days on Which Daily N-back Sessions Were Completed — 95.63 percentage of days
Actinic Keratosis
Primary: Number of Subjects With Complete Clearance of AK Lesions — 30.2; 25.7; 9.5 percentage of participants — p=<0.0001
Smallpox
Primary: Related Serious Adverse Events — 0; 0 Participants
Cancer
Primary: Mean Patient-centered Communication in Advanced Cancer Score — 0.16; -0.01 standardized score on a scale — p=0.05
Septic Shock
Primary: Organ-failure-free Days — 26 units on a scale
Breast Cancer
Primary: Injection Site Clearance for Lymphoseek and 99mTc-Sulfur Colloid (SC). — 1.78; 0.045 minutes
Tobacco Use in Childbirth · Smoking Cessation · Pregnancy Related
Primary: Change in Cigarettes Per Day From Baseline to 4-weeks — -0.94; 0 Cigarettes smoked per day
Opioid Dependence · Pain
Primary: Pain Threshold — 18.72; 24.78; 16.16; 24.37 seconds
Smoking Cessation
Primary: Smoking Abstinence — 21; 8 Participants
Smallpox
Primary: Percentage of Participants With Seroconversion by ELISA — 98.9; 82.2; 3.4; 95.5 percentage of subjects